Mesenchymal stem cell therapy for liver disease: current status and future perspectives.

Published on May 1, 2021in Current Opinion in Gastroenterology3.225
· DOI :10.1097/MOG.0000000000000724
Young Woo Eom17
Estimated H-index: 17
Yongdae Yoon , Soon Koo Baik42
Estimated H-index: 42
PURPOSE OF REVIEW Liver transplantation is the gold standard for the treatment of end-stage liver disease. However, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy. RECENT FINDINGS MSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. Additionally, MSCs can be noninvasively isolated from various tissues and expanded ex vivo in sufficient numbers for clinical evaluation. SUMMARY Currently, there is no approved MSC therapy for the treatment of liver disease. However, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.
#1Yoo Li Lim (Yonsei University)H-Index: 7
#2Young Woo Eom (Yonsei University)H-Index: 17
Last. Moon Young Kim (Yonsei University)H-Index: 32
view all 8 authors...
Background and objectives Autologous or allogeneic bone marrow-derived mesenchymal stem cells (BMSCs) have been applied in clinical trials to treat liver disease. However, only a few studies are comparing the characteristics of autologous MSCs from patients and allogeneic MSCs from normal subjects. Methods and results We compared the characteristics of BMSCs (BCs and BPs, respectively) isolated from six healthy volunteers and six patients with cirrhosis. In passage 3 (P3), senescent population a...
1 CitationsSource
#1Xue YangH-Index: 13
#2Yan MengH-Index: 3
Last. Chen ZongH-Index: 9
view all 6 authors...
Liver disease is a major health problem that endangers human health worldwide. Currently, whole organ allograft transplantation is the gold standard for the treatment of end-stage liver disease. A shortage of suitable organs, high costs and surgical complications limit the application of liver transplantation. Mesenchymal stem cell therapy has been considered as a promising alternative approach for end-stage liver disease. Some clinical trials have confirmed the effectiveness of MSC therapy for ...
3 CitationsSource
#1Yifan Jia (SYSU: Sun Yat-sen University)H-Index: 1
#2Xin Shu (SYSU: Sun Yat-sen University)H-Index: 6
Last. Yang Yang (SYSU: Sun Yat-sen University)H-Index: 1
view all 10 authors...
BACKGROUND Umbilical cord mesenchymal stem cells (UCMSCs) have been demonstrated to have good therapeutic effects in the treatment of HBV-related liver diseases. However, the therapeutic effect of UCMSCs on HBV-related liver failure and liver cirrhosis and the variations in the efficacy of UCMSCs after different treatment courses remain poorly understood. Therefore, this study was designed to answer these two questions. METHODS This was an observational study that retrospectively considered a 3-...
3 CitationsSource
#1Young Woo EomH-Index: 17
#2Seong Hee Kang (Yonsei University)H-Index: 10
Last. Soon Koo BaikH-Index: 42
view all 5 authors...
Mesenchymal stem cells (MSCs) are being developed for stem cell therapy and can be efficiently used in regenerative medicine. To date, more than 1,000 clinical trials have used MSCs; of these, more than 80 clinical trials have targeted liver disease. MSCs migrate to damaged liver tissues, differentiate into hepatocytes, reduce liver inflammatory responses, reduce liver fibrosis, and act as antioxidants. According to the reported literature, MSCs are safe, have no side effects, and improve liver ...
1 CitationsSource
#1Haitham M. Abdelbary (Ain Shams University)H-Index: 1
#2Rasha Magdy (Ain Shams University)H-Index: 1
Last. Inas Abdelmoaty (Ain Shams University)H-Index: 1
view all 4 authors...
BACKGROUND: Hepatic complications are a well-known cause of both early and late mortality and morbidity in hematopoietic stem cell transplant (HSCT) recipients. Early diagnosis and management of hepatic complications is important in order to commence appropriate therapy. Conditioning regimens, acute and chronic graft versus host disease, sinusoidal obstruction syndrome, and infections among others represent major hepatic complications for the transplant recipient. We assessed liver function test...
1 CitationsSource
#2Raquel M. A. PaivaH-Index: 1
Last. Oswaldo Keith Okamoto (USP: University of São Paulo)H-Index: 26
view all 6 authors...
Graft versus host disease (GVHD) is a common condition in patients subjected to allogeneic hematopoietic stem cell transplantation. The immune cells derived from the grafted stem cells attack recipient’s tissues, including those from the skin, liver, eyes, mouth, lungs, gastrointestinal tract, neuromuscular system and genitourinary tract, may lead to severe morbidity and mortality. Acute GVHD can occur within few weeks after the allogeneic cells have engrafted in the recipient while chronic GVHD...
17 CitationsSource
#1Wenxiong Xu (SYSU: Sun Yat-sen University)H-Index: 8
#2Hong-liang He (USTC: University of Science and Technology of China)H-Index: 1
Last. Jianguo Li (SYSU: Sun Yat-sen University)H-Index: 2
view all 9 authors...
Background. Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a common type of liver failure with a high mortality. This study aimed at investigating the safety and efficacy of the combination treatment of plasma exchange (PE) and umbilical cord-derived mesenchymal stem cell (UC-MSCs) transplantation for HBV-ACLF patients. Methods. A total of 110 HBV-ACLF patients treated in our hospital from January 2012 to September 2017 were enrolled into this trial and divided into the c...
14 CitationsSource
#1Doaa Abdeltawab (Assiut University)H-Index: 2
#1Saad Zaki Mahmoud (Assiut University)H-Index: 1
Last. AlaaSoliman Abd-Elkader (Assiut University)H-Index: 1
view all 6 authors...
Introduction The high prevalence of hepatitis C virus-associated liver disease has led to increasing number of Egyptian patients having end-stage liver disease and requiring liver transplantation. Because of several limitations of liver transplantation, new alternative treatment modalities are required for patients with liver cirrhosis. Many study results encourage the use of autologous bone marrow-derived mesenchymal stem cells (MSCs) for liver diseases. Aim The aim of this study was to assess ...
#1Mohammed Alfaifi (University of Birmingham)H-Index: 1
#2Young Woo Eom (Yonsei University)H-Index: 17
Last. Soon Koo Baik (Yonsei University)H-Index: 42
view all 4 authors...
Summary The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in ...
50 CitationsSource
#1Xueqing FangH-Index: 2
#2Liwei LiuH-Index: 1
Last. Xi ChenH-Index: 2
view all 14 authors...
BACKGROUND AND AIM: The aim of our study was to investigate the immunomodulatory effect and short-term efficacy and long-term prognosis of decompensated liver cirrhosis patients caused by hepatitis B after a double transplantation with human umbilical cord mesenchymal stem cells (hUCMSCs). METHODS: Fifty inpatients were recruited and given the same medical treatments, receiving hUCMSCs injection intravenously. Fifty-three patients (Group B) matched for age, sex, and baseline alanine aminotransfe...
9 CitationsSource
Cited By0